FDA issues new clinical research warning letters

被引：0

|

作者：

不详

机构：

来源：

JOURNAL OF INVESTIGATIVE MEDICINE | 2002年 / 50卷 / 05期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

收藏

页码：344 / 345

页数：2

相关论文

共 50 条

[1] FDA Issues Warning Letters About Claims Regarding Lipodissolve
不详
[J]. JOURNAL OF DRUGS IN DERMATOLOGY, 2010, 9 (07) : 874 - 874
[2] FDA issues warning letters about unapproved eye disorder therapies
[J]. Reactions Weekly, 2023, 1975 (1) : 6 - 6
[3] FDA issues warning about 'new' tamoxifen risk
Twombly, R
[J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2002, 94 (15) : 1122 - 1122
[4] FDA issues warning letter
不详
[J]. FOOD TECHNOLOGY, 2007, 61 (06) : 12 - 13
[5] FDA issues warning on domperidone
不详
[J]. CHEMICAL & ENGINEERING NEWS, 2004, 82 (24) : 25 - 25
[6] FDA issues ephedrine warning
不详
[J]. JOURNAL OF THE AMERICAN DIETETIC ASSOCIATION, 1996, 96 (06) : 557 - 557
[7] FDA issues warning on propofol (Diprivan)
不详
[J]. CANADIAN MEDICAL ASSOCIATION JOURNAL, 2001, 164 (11) : 1608 - 1608
[8] FDA Issues Warning on Ketamine Compounds
Roush, Karen
[J]. AMERICAN JOURNAL OF NURSING, 2024, 124 (01) : 11 - 11
[9] US FDA issues astemizole warning
[J]. Reactions Weekly, 1998, 688 (1) : 2 - 2
[10] FDA Issues Warning on Regadenoson and Adenosine
不详
[J]. JOURNAL OF NUCLEAR MEDICINE, 2014, 55 (01)

← 1 2 3 4 5 →